ReviewInternational journal of endocrinology2013
Pharmacogenetics of oral antidiabetic drugs.
Review in International journal of endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Limited sampling strategy for determining metformin area under the plasma concentration-time curve.British journal of clinical pharmacology · 2016Trial
- Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus.Journal of the ASEAN Federation of Endocrine Societies · 2023Article
- Determinants in Tailoring Antidiabetic Therapies: A Personalized Approach.Global medical genetics · 2022Review
- Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients.Journal of diabetes and metabolic disorders · 2021Article
- Genetic and Epigenomic Modifiers of Diabetic Neuropathy.International journal of molecular sciences · 2021Review
- Utility of Precision Medicine in the Management of Diabetes: Expert Opinion from an International Panel.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- Article
- Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.Frontiers in pharmacology · 2018Article
- Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes.Diabetologia · 2017Article
- The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Diabetes care · 2016Article
- Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.Human molecular genetics · 2016Article
- Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes.International journal of molecular sciences · 2016Article
- Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery.Nature reviews. Endocrinology · 2016Review
- Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.Scientific reports · 2016Article
- Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.International journal of molecular and cellular medicine · 2016Article
- Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents.Pharmacogenomics and personalized medicine · 2016Review
- Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.Clinical and experimental medicine · 2015Article
- A Comprehensive Review of Drug-Drug Interactions with Metformin.Clinical pharmacokinetics · 2015Review
- Genetics of drug response in type 2 diabetes.Current diabetes reports · 2015Review
- Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?PPAR research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations detected in these studies were replicated. The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 were associated with the effect of sulfonylureas. CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K(+) channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. SLC22A1, SLC47A1, and ATM gene variants were repeatedly associated with the response to metformin. SLC22A1 and SLC47A1 encode metformin transporters OCT1 and MATE1, respectively. The function of a gene variant near ATM gene identified by a genome-wide association study is not elucidated so far. The first variant associated with the response to gliptins is a polymorphism in the proximity of CTRB1/2 gene which encodes chymotrypsinogen. Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.